Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discovery that is…
Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with nearly…
AI-based drug developer Insilico Medicine said it plans to advance its lead candidate ISM001-055 into a potentially pivotal study, after generating positive topline results in a Phase IIa trial showing…
As the amount of genomic data grows, so too does the challenge of organizing it into a usable database. Indeed, the lack of a searchable database of genomic information from…
As the amount of genomic data grows, so too does the challenge of organizing it into a usable database. Indeed, the lack of a searchable database of genomic information from…
A collaboration between Parse Biosciences’ GigaLab and Vevo Therapeutics has generated what they say is the largest single-cell dataset to date. The Tahoe-100M dataset comprises 100 million cells and covers…
Five years after launching Enveda with $55,000 of personal savings, Viswa Colluru, PhD, CEO, saw his initial investment in the AI-powered developer of plant-based treatments more than pay off recently…
Colin HillCo-Founder, CEO, Aitia More than two decades ago, physicists-by-training Colin Hill and Iya Khalil, PhD, co-founded Gene Network Sciences (GNS), a biosimulation company based in Somerville, MA, on the…
Eppendorf and DataHow agreed to a strategic collaboration aimed at transforming bioprocess development by integrating DataHow’s AI-enabled analytics solution, DataHowLab, with Eppendorf’s cloud-based monitoring and analytics platform, BioNsight®. The integration…
Big investments in artificial intelligence (AI) don’t guarantee big wins. This point was emphasized by Niven R. Narain, the president and CEO of BPGbio president and CEO Niven R. Narain,…
